Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in BCG-Refractory Urothelial Carcinoma with FGFR3 Mutations
NCT01732107Phase 2Terminated
- Start
- Mar 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dovitinib in urothelial carcinoma (UC). Started Mar 2013; status: terminated.
02
Drugs
dovitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01732107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732107.